Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Employment/Membership › Details

C4 Therapeutics–Hirsch A: management, 202009– CEO before Agios Pharmaceuticals + BIND Therapeutics + Avila Therapeutics + Biogen


Period Period 2020-09-08
Organisations Organisation C4 Therapeutics Inc. (C4T)
  Organisation 2 Agios Pharmaceuticals
Products Product protein degradation drug
  Product 2 protein degradation technology
Persons Person Hirsch, Andrew (C4 Therapeutics 202009– CEO before Agios Pharmaceuticals + BIND Therapeutics + Avila Therapeutics)
  Person 2 Cohen, Marc (C4 Therapeutics 202009– Executive Chairman before interim CEO + Co-Founder)

C4 Therapeutics, Inc.. (9/8/20). "Press Release: Andrew Hirsch Named Chief Executive Officer of C4 Therapeutics". Watertown, MA.

C4 Therapeutics, Inc. (C4T), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced the hiring of Andrew Hirsch as the Company’s incoming chief executive officer. Mr. Hirsch comes to C4T from Agios Pharmaceuticals where he was chief financial officer and head of corporate development. Marc Cohen, co-founder, interim chief executive officer, and executive chairman will remain as executive chairman of the Company.

“Andrew’s more than 20 years of leadership experience in the biotechnology industry across pre-clinical, clinical and commercial-stage companies make him the perfect choice to lead C4T into the next phase of its growth as we advance our pipeline of novel targeted protein degraders into the clinic,” commented Mr. Cohen.

“I am thrilled to be joining C4T, which is a leader in developing this exciting new modality of medicines,” commented Mr. Hirsch. “I am passionate about improving the lives of patients and believe that C4T’s proprietary technology platform has the ability to develop novel therapeutic candidates to target and eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. This approach offers a tremendous opportunity to make a lasting impact on patient outcomes.”

Mr. Hirsch has more than 20 years of experience in a range of strategic and operating roles, including over 15 years in the biotechnology industry. Prior to his time at Agios, Mr. Hirsch served as President and Chief Executive Officer of BIND Therapeutics and Chief Financial Officer at Avila Therapeutics, until its acquisition by Celgene. Prior to that, he held roles of increasing responsibility during his nearly 10-year tenure at Biogen, including Vice President of Corporate Strategy and M&A and Program Executive for the Tecfidera development team. He currently serves on the board of directors at Editas Medicine. Mr. Hirsch holds an MBA from the Tuck School at Dartmouth College and a Bachelor of Arts in Economics from the University of Pennsylvania.

About C4 Therapeutics

C4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit

Media Contact:

Caroline Rufo, Ph.D.

Record changed: 2020-09-17


Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px

More documents for C4 Therapeutics Inc. (C4T)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top